Recombinant ApxIV protein enhances protective efficacy against<i>Actinobacillus pleuropneumoniae</i>in mice and pigs

Wu, Heng; Yeh, Peir-En; Hsueh, Kai Jen; Yang, Wen; Chu, Chiayung

doi:10.1111/jam.13726

Cited by 14 publications

(17 citation statements)

References 27 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that herbal additives can change the composition of intestinal bacterial communities of fish (Büyükdevecia et al, 2018;Meng et al, 2019;Wu, Yeh, Hsueh, Yang, & Chu, 2018).…”

Section: Discussionmentioning

confidence: 99%

Effects of Chinese yam ( Dioscorea oppositifolia L .) dietary supplementation on intestinal microflora, digestive enzyme activity and immunity in rainbow trout ( Oncorhynchus mykiss )

Wang

Liu

et al. 2020

Aquac Res

View full text Add to dashboard Cite

The intensive and semi-intensive cultivation is widely used in aquaculture and easily causes disease outbreaks bringing about the loss of aquatic products. Furthermore, factors including overcrowding, sudden changes of temperature, the deterioration of water quality, and inadequate feeding and management could result in immunosuppression in aquatic animals and thus increasing the susceptibility to certain infectious diseases (Awad & Awaad, 2017). In order to prevent and cure the infectious diseases, some antimicrobials have been extensively used in aquaculture industries. However, antibiotics and some chemotherapy treating diseases inevitably lead to

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Chinese yam ( Dioscorea oppositifolia L .) dietary supplementation on intestinal microflora, digestive enzyme activity and immunity in rainbow trout ( Oncorhynchus mykiss )

Wang

Liu

et al. 2020

Aquac Res

View full text Add to dashboard Cite

show abstract

“…Current commercial vaccines cannot provide complete protection because the fixed antigen that induce complete immune protection have not been identified (Rycroft and Garside 2000). Some scholars have found that the recombinant ApxIV protein combined with inactivated APP1, known as a multicomponent vaccine, has a good protective effect against both homologous and heterologous A. pleuropneumoniae (Wu et al 2018). In this study, the immunization with the combined vaccine addressed the defects of inactivated A. pleuropneumoniae and RTA protein alone, reducing the clinical symptoms and improving the survival rate of A. pleuropneumoniae-infected mice.…”

Section: Discussionmentioning

confidence: 99%

“…There are 18 serovars of A. pleuropneumoniae (Bosse et al 2018;Liu et al 2018), and the lack of cross immunoprotection among the major serovars has slowed the development of a vaccine. At present, research on an A. pleuropneumoniae vaccine has focused on the pilus protein (Sadilkova et al 2012), lipopolysaccharide (Li et al 2018), outer membrane protein (Xie et al 2016), adhesion (Zhou et al 2013) and A. pleuropneumoniae toxin (Apx) exotoxin (Wu et al 2018), which are involved in colonization, maintenance, lesion induction and host defense escape (Chiers et al 2010). Apx toxins can be divided into four types, Apx I-IV; Apx IV exists in all serovars of A. pleuropneumoniae strains (Schaller et al 1999) and is necessary for virulence (Liu et al 2009).…”

Section: Introductionmentioning

confidence: 99%

Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice

et al. 2020

View full text Add to dashboard Cite

Actinobacillus pleuropneumoniae (A. pleuropneumoniae/APP) is the pathogen that causes porcine contagious pleuropneumonia. Actinobacillus pleuropneumoniae is divided into 18 serovars, and the cross protection efficacy of epitopes is debatable, which has resulted in the slow development of a vaccine. Consequently, epitope-based vaccines conferring Actinobacillus pleuropneumoniae cross protection have rarely been reported. In this study, B cell epitopes in the head domain of trimeric autotransporter adhesin were predicted, and 6 epitopes were selected. Then, the predicted epitopes (Ba1, Bb5, C1, PH1 and PH2) were connected by linkers to construct a recombinant tandem antigen (rta) gene. The RTA protein encoded by the recombinant rta gene was expressed, and finally the ICR mice were immunized with the RTA protein with or without inactivated Actinobacillus pleuropneumoniae (serovars 1 and 5b) and challenged with Actinobacillus pleuropneumoniae to evaluate the protective effect of the epitope-based vaccine and combined vaccine. The mice in the RTA-immunized group and RTA plus inactivated Actinobacillus pleuropneumoniae vaccine group had a significant improvement in clinical symptoms and a higher level of antibody in the serum than those in the control group. The RTA immune group had a 40% survival rate after Actinobacillus pleuropneumoniae infection, whereas the combination of RTA and inactivated Actinobacillus pleuropneumoniae produced very strong cross immune protection in mice, at least 50% (RTA IB1 + C5) and at most 100% (RTA IB5 + C1), whereas no cross immunoprotection was found in the solo Actinobacillus pleuropneumoniae immune group. Overall, the combination of the RTA protein and inactivated bacteria significantly enhanced the cross protection effects. This implies that RTA protein in combination with a suitable inactivated Actinobacillus pleuropneumoniae strain could be a candidate vaccine for porcine contagious pleuropneumonia.

show abstract

“…pleuropneumoniae (Wu et al 2018). In this study, the immunization with the combined vaccine addressed the defects of inactivated A. pleuropneumoniae and RTA protein alone, reducing the clinical symptoms and improving the survival rate of A. pleuropneumoniae-infected mice.…”

Section: Discussionmentioning

confidence: 99%

“…are 18 serovars of A. pleuropneumoniae (Bosse et al 2018;Liu et al 2018), and the lack of cross immunoprotection among the major serovars has slowed the development of a vaccine. At present, research on an A. pleuropneumoniae vaccine has focused on the pilus protein (Sadilkova et al 2012), lipopolysaccharide (Li et al 2018), outer membrane protein (Xie et al 2016), adhesion (Zhou et al 2013) and A. pleuropneumoniae toxin (Apx) exotoxin (Wu et al 2018), which are involved in colonization, maintenance, lesion induction and host defense escape (Chiers et al 2010). Apx toxins can be divided into four types, Apx I-IV; Apx IV exists in all serovars of A. pleuropneumoniae strains (Schaller et al 1999) and is necessary for virulence (Liu et al 2009).…”

mentioning

confidence: 99%

Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice

Xiao

Liu

Bao

et al. 2020

Preprint

View full text Add to dashboard Cite

Actinobacillus pleuropneumoniae (A. pleuropneumoniae/APP) is the pathogen that causes porcine contagious pleuropneumonia. Actinobacillus pleuropneumoniae is divided into 18 serovars, and the cross protection efficacy of epitopes is debatable, which has resulted in the slow development of a vaccine. Consequently, epitope-based vaccines conferring Actinobacillus pleuropneumoniae cross protection have rarely been reported. In this study, B cell epitopes in the head domain of trimeric autotransporter adhesin were predicted, and 6 epitopes were selected. Then, the predicted epitopes (Ba1, Bb5, C1, PH1 and PH2) were connected by linkers to construct a recombinant tandem antigen (rta) gene. The RTA protein encoded by the recombinant rta gene was expressed, and finally the ICR mice were immunized with the RTA protein with or without inactivated Actinobacillus pleuropneumoniae (serovars 1 and 5b) and challenged with Actinobacillus pleuropneumoniae to evaluate the protective effect of the epitope-based vaccine and combined vaccine.The mice in the RTA-immunized group and RTA plus inactivated Actinobacillus pleuropneumoniae vaccine group had a significant improvement in clinical symptoms and a higher level of antibody in the serum than those in the control group. The RTA immune group had a 40% survival rate after Actinobacillus pleuropneumoniae infection, whereas the combination of RTA and inactivated Actinobacillus pleuropneumoniae produced very strong cross immune protection in mice, at least 50% (RTA IB1+ C5) and at most 100% (RTA IB5 + C1), whereas no cross immunoprotection was found in the solo Actinobacillus pleuropneumoniae immune group. Overall, the combination of the RTA protein and inactivated bacteria significantly enhanced the cross protection effects. This implies that RTA protein in combination with a suitable inactivated Actinobacillus pleuropneumoniae strain could be a candidate vaccine for porcine contagious pleuropneumonia.

show abstract

Recombinant ApxIV protein enhances protective efficacy againstActinobacillus pleuropneumoniaein mice and pigs

Abstract: The addition of ApxIV to the multicomponent vaccine could enhance homologous and heterologous protection in mice and pigs, respectively, against challenge by A. pleuropneumoniae.

Cited by 14 publications

References 27 publications

Effects of Chinese yam ( Dioscorea oppositifolia L .) dietary supplementation on intestinal microflora, digestive enzyme activity and immunity in rainbow trout ( Oncorhynchus mykiss )

Effects of Chinese yam ( Dioscorea oppositifolia L .) dietary supplementation on intestinal microflora, digestive enzyme activity and immunity in rainbow trout ( Oncorhynchus mykiss )

Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice

Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice

Contact Info

Product

Resources

About